Nonmetastatic castration-resistant prostate cancer: Novel agents to treat a lethal disease

Nonmetastatic castration-resistant prostate cancer (nmCRPC) - defined as prostate-specific antigen (PSA) > 2 ng/mL, testosterone castration levels < 1.7 nm/L, and the absence of metastatic lesions on conventional imaging (computed tomography or bone scan) - has been defined as a lethal disease...

Descripción completa

Detalles Bibliográficos
Autores principales: Henriquez, Ivan, Spratt, Daniel, Gómez-Iturriaga, Alfonso, Abuchaibe, Oscar, Couñago, Felipe
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Baishideng Publishing Group Inc 2021
Materias:
Editorial
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7829629/
https://www.ncbi.nlm.nih.gov/pubmed/33552935
http://dx.doi.org/10.5306/wjco.v12.i1.6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7829629/
https://www.ncbi.nlm.nih.gov/pubmed/33552935
http://dx.doi.org/10.5306/wjco.v12.i1.6

Ejemplares similares